TAK-188: Antibody-Drug Conjugate Targeting CCR8+ Tregs for Anti-Tumor Immunity

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1A phase 1/2, first-in-human, open-label, dose-escalation and -expansion study of TAK-188, a novel antibody-drug conjugate (ADC) targeting CCR8 ⁺ regulatory T cells, in adult patients with locally advanced or metastatic solid tumors.2026
2. 2Abstract 718: CCR8 antibody drug conjugates: Targeting regulatory T cells for tumor sensitization2024
3. 3Abstract 6350: 2MW4691, a novel CCR8/CTLA-4 bispecific antibody, displays potent anti-tumor efficacy by specifically depeleting tumor-infiltrating Tregs and blocking CTLA-4 signaling on CD8+ T cells2024 · 1 citations
4. 4Abstract LB130: Identification of fully human CCR8 antibodies that demonstrate excellent ADCC function, potent blocking activity, and robust anti-tumor immune responses2024
5. 5225Actinium-armed antibody targeting CCR8+ regulatory T cells synergizes with immunotherapy to promote tumor rejection in syngeneic colorectal cancer models2025 · 3 citations